A high-quality income-focused investment trust to buy now
First-rate companies with sustainable returns are the key to long-term dividend growth for the Murray Income Trust.
It’s easy to assume that an investment trust with the word “income” in its title is very much in the “value” camp, investing in companies with high dividends but that are mature, declining or mis-managed businesses.
Charles Luke, the manager of the £1bn Murray Income Trust (LSE: MUT) has different ideas, emphasising the importance of “quality” companies. This means those with high returns on invested capital based on the durability of the business model, the attractiveness of the industry, the strength of its financials, the capability of its management and a good environmental, social and governance (ESG) profile.
“The academic evidence is very clear,” he says. “Good quality companies out-perform because the market systematically underestimates the sustainability of their returns. Quality is the key to long-term success.” The price of this is a portfolio “that is a little bit expensive in terms of valuation, a price/earnings ratio of perhaps two to three points higher than the market”.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The trust, which invests primarily in UK equities, yields 3.8% and has increased its dividend annually for the last 48 years. The compound growth rate over that period is 9.4%.The yield is helped by the 6% discount to net asset value (NAV) at which the shares trade and its low costs (a total expenses ratio below 0.5%), but a yield well above the All Share index’s 3.1% is still impressive.
A well-diversified portfolio
The yield is not boosted by having a third of the portfolio in mid-cap stocks, generally lower yielding than the FTSE 100, and 12% of the portfolio invested overseas. This is balanced by low-cost borrowings, amounting to 9% of NAV, the capitalisation of 70% of interest and management costs, and an option writing strategy that accounts for 5%-7% of total income. Luke calls this “a tried and tested process that we have been doing for over ten years”.
The portfolio has 61 holdings, none larger than 5%, and is well-diversified by sector. The largest holdings are AstraZeneca, Diageo, RELX and SSE but the overlap with the FTSE All-Share index is just 30%. The overseas investments, which can be up to 20% of the total, enable Luke “to invest in better quality versions of UK companies” such as Total rather than Shell “and in companies in industries that aren’t available to UK investors”, such as VAT Group, the market leader in vacuum valve technology.
Mid-cap holdings give access “high-quality domestic companies” such as Genuit (plastic piping) and Howden Joinery (fitted kitchens), and also firms with “under-appreciated quality” such as Convatec (medical products) and Inchcape (international car dealerships)”. Luke is also prepared to invest in companies with low yields but growth potential, such as Dechra Pharmaceuticals and the technology group Aveva.
A strong all-round performer
The result is both an attractive and growing yield and one of the best performance records in the UK. Investment returns to the end of 2021 were 18% over one year, 45% over three and 47% over five – the latter two 17 percentage points ahead of the All Share index. Moreover, Luke can point to a strong record of capital preservation. In the last ten years, the trust has marginally under-performed in up months for the market but significantly out-performed in down months.
“UK equity valuations remain compelling compared with other markets, the UK offers compelling global growth opportunities and international investors are underweight, despite the proliferation of bid activity,” reckons Luke. London cannot swim against what is currently an adverse tide in stockmarkets but the yield and record of resilience in tough times should reassure investors and pay them to wait, confident that the trust is well positioned for better times.
Merryn Somerset Webb is a non-executive director of Murray Income Trust.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Max has an Economics degree from the University of Cambridge and is a chartered accountant. He worked at Investec Asset Management for 12 years, managing multi-asset funds investing in internally and externally managed funds, including investment trusts. This included a fund of investment trusts which grew to £120m+. Max has managed ten investment trusts (winning many awards) and sat on the boards of three trusts – two directorships are still active.
After 39 years in financial services, including 30 as a professional fund manager, Max took semi-retirement in 2017. Max has been a MoneyWeek columnist since 2016 writing about investment funds and more generally on markets online, plus occasional opinion pieces. He also writes for the Investment Trust Handbook each year and has contributed to The Daily Telegraph and other publications. See here for details of current investments held by Max.
-
How to invest in nuclear power
We need nuclear power to go green, says Dominic Frisby. But there is a better option than huge power stations
By Dominic Frisby Published
-
Chase slashes its easy-access savings rate – is it time to switch?
The Chase easy-access savings account has proved popular with savers thanks to its competitive rate and bonus deals. But, as the rate has dropped, has it lost its charm?
By Katie Williams Published
-
Pfizer shares rise as US investor takes $1 billion stake
Pfizer shares are on the up since US activist investor Starboard Value built up a stake in the drug maker. But strategic options appear limited
By Dr Matthew Partridge Published
-
Is China an undervalued market?
Most funds remain wary of China amid slowing growth. Have they got it wrong?
By Max King Published
-
A fairer deal for investment trusts
New rules on how investment trusts report costs should ditch the idea that investors only need to look at one number
By Cris Sholto Heaton Published
-
Qualcomm could acquire rival Intel – but securing the deal won't be easy
A tie-up between Qualcomm and its semiconductor rival Intel would be a coup. But multiple regulatory and commercial hurdles lie ahead.
By Dr Matthew Partridge Published
-
After Priips changes, investment trusts are due a rerating
Heavy-handed rules governing fees, which put investment trust companies at a disadvantage, are to go.
By Rupert Hargreaves Published
-
Top trusts that offer growth at a discount
Professional investor Alastair Laing picks three trusts where he'd put his money
By Alastair Laing Published
-
How to invest in the quiet market months
Here's how to invest in the quiet market months, since “sell in May” hasn’t paid off this year.
By Cris Sholto Heaton Published
-
Spire Healthcare: invest in the booming demand for private healthcare
Spire Healthcare is one of the few listed companies benefiting from the growing trend in private healthcare. Should you invest?
By Rupert Hargreaves Published